During a live event, Christine Bestvina, MD, discussed trials of KRAS inhibitors plus immunotherapy in patients with ...

Breakthrough Therapy Designation granted to elironrasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received prior ...

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, highlights Emrelis’ potential to broaden its clinical impact ...

New long-term data from the Phase III FLAURA2 trial confirm that Tagrisso combined with chemotherapy delivers a significant overall survival benefit over monotherapy in patients with advanced ...

Revolution Medicines was granted breakthrough therapy designation for elironrasib, a potential non-small cell lung cancer treatment.

During a live event, Bruna Pellini, MD, discussed IO monotherapy as a first-line option for non–small cell lung cancer with ...

Q2 2025 has demonstrated the pharmaceutical industry’s continued momentum in developing transformative therapies across ...

Radiation therapy, once thought of mainly as a local cancer treatment, is now showing power to awaken the immune system in surprising ways. Researchers discovered that combining radiation with ...

Revolution Medicines (RVMD) announced that the U.S. Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, to ...

Patients with rheumatoid arthritis who undergo immune checkpoint inhibition for metastatic non-small cell lung cancer demonstrate similar overall survival as those without RA, according to data ...

Castle Biosciences' DecisionDx-Melanoma test and Revolution Medicines' elironrasib cancer drug receive FDA Breakthrough Designations. Read more here.

Researchers saw some cases where a patient’s own autoantibodies boosted likelihood of responding to checkpoint blockade.